This federal Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $49,990,000 single-award IDC has an ultimate completion date of June 30, 2028 and does not have a set-aside designation.
Under this IDC, Mriglobal is providing a range of scientific research, testing, and product development services to support NCI's cancer prevention research efforts. This includes managing a centralized repository of chemopreventive agents and providing chemistry support services. Specific task orders awarded to date total over $30 million and cover activities such as the manufacture of plasmid DNA drug substance and product, as well as production of drug substance, drug product, and placebo for clinical trials. Mriglobal has extensive experience supporting federal agencies like NIH, CDC, and BARDA through prime contracts and subcontracts for specialized capabilities in areas like biorepository management, pharmaceutical manufacturing, and infectious disease research.
Generated 3/1/25, 10:05 AM